Bon Natural Life Ltd
BON evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BON—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BON
Bon Natural Life Ltd (BON) is a China-based nutraceutical and personal care ingredients company that manufactures and distributes health supplements, functional foods, and cosmetic ingredients, with recent capital raises supporting expansion but facing significant capital needs and competitive pressures.
Key risk: Capital dependency
Market Cap
$11.6M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Sep 30, 2025.
Tracking 2 clinical trials for Bon Natural Life Ltd.
Bon Natural Life Ltd (BON) is a China-based nutraceutical and personal care ingredients company that manufactures and distributes health supplements, functional foods, and cosmetic ingredients, with recent capital raises supporting expansion but facing significant capital needs and competitive pressures.
- As of September 30, 2025, the company had cash and restricted cash of $6.3 million and working capital of $19.5 million [sec · filed 2026-01-23].
- For the year ended September 30, 2025, the company reported a net loss of approximately $2.0 million [sec · filed 2026-01-23].
- In 2024, the company closed a private offering of shares for $5.6 million, and in March 2025, a public offering for $10.7 million [sec · filed 2026-01-23].
- Research and development expenses were 4.0% of revenues for the year ended September 30, 2025, down from 6.8% in the prior year [sec · filed 2026-01-23].
- The company faces a need for approximately $30 million in additional capital to fund its expansion plans [sec · filed 2026-01-23].
What works
- The company successfully raised $16.3 million through private and public offerings in 2024 and 2025, providing near-term liquidity [sec · filed 2026-01-23].
- Total assets grew to $85.2 million as of September 30, 2025, up from $61.8 million a year earlier, indicating balance sheet expansion [sec · filed 2026-01-23].
- The company has a broad product portfolio spanning health supplements, functional foods, and personal care ingredients, allowing diversification [sec · filed 2026-01-23].
What to weigh
- The company reported a net loss of $2.0 million for fiscal 2025, and operating cash flow was negative $4.3 million in the first half of fiscal 2025 [sec · filed 2026-01-23][sec · filed 2025-09-29].
- Management estimates capital needs of approximately $30 million for expansion, and failure to secure additional financing could impair business plans [sec · filed 2026-01-23].
- The nutraceutical industry is characterized by rapid product changes and intense competition, and the company may not respond in a timely manner [sec · filed 2026-01-23].
- As of September 30, 2025, the company had $12.2 million in outstanding bank loans, with $10.2 million due short-term, creating refinancing risk [sec · filed 2026-01-23].
From the filings
Quoted directly from source documents.
Net loss for fiscal 2025
“For the year ended September 30, 2025, the Company realized approximately $2.0 million net loss.”
SEC filings · January 23, 2026
Capital needs for expansion
“Management estimates that our capital needs for expansion will be approximately $30 million.”
SEC filings · January 23, 2026
R&D spending as percentage of revenue
“Research and development expenses were 4.0%, 6.8% and 1.0% of our revenues for the years ended September 30, 2025, 2024 and 2023, respectively.”
SEC filings · January 23, 2026
Risks & what to watch (4)›
Key risks
- Capital dependency — Company needs ~$30M additional capital; failure to raise may impair business plan [sec · filed 2026-01-23].
- Negative operating cash flow — Operating cash flow was -$4.3M in H1 2025, indicating cash burn [sec · filed 2025-09-29].
- Short-term debt burden — $10.2M in short-term bank loans due within a year as of Sep 30, 2025 [sec · filed 2026-01-23].
- Industry competition and obsolescence — Rapid product changes and new entrants could render offerings obsolete [sec · filed 2026-01-23].
What to watch
- Ability to raise the estimated $30 million in additional capital for expansion [sec · filed 2026-01-23].
- Trend in net losses and operating cash flow, especially if cash burn continues [sec · filed 2025-09-29].
- Renewal or refinancing of $10.2 million in short-term bank loans [sec · filed 2026-01-23].
- New product introductions and market response in the competitive nutraceutical sector [sec · filed 2026-01-23].
Sources: SEC filings · Generated August 28, 2026 · How we verify sources →
Run Bon Natural Life Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Bon Natural Life Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$21K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 15,900 | $21K |
| osaic holdings, inc. | 1 | $1 |
Short Interest
as of May 20, 2026- % of float
- 0.3%
- Days to cover
- 1.0
- Shares short
- 18,352
- Daily short volume (Jul 23, 2026)
- 51.0%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BON short interestFrequently asked questions
What is the AI investment thesis for Bon Natural Life Ltd?
Bon Natural Life Ltd (BON) is a China-based nutraceutical and personal care ingredients company that manufactures and distributes health supplements, functional foods, and cosmetic ingredients, with recent capital raises supporting expansion but facing significant capital needs and competitive pressures.
Who is the CEO of Bon Natural Life Ltd?
Mr. Yongwei Hu is the chief executive officer of Bon Natural Life Ltd (BON).
Where is Bon Natural Life Ltd headquartered?
Bon Natural Life Ltd (BON) is headquartered in Xi'an, China.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.